Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Marion is building on its R&D route to the Orient via a joint venture agreement with the Cardizem connection Tanabe. Marion announced the agreement in an Aug. 30 press release. Marion said it has signed an agreement in principle to establish a U.S. joint venture with the Japanese firm Tanabe Seiyaku "for the purpose of developing, licensing and marketing, and ultimately manufacturing certain Tanabe compounds in the U.S. and Canada." The "initial phase" of the partnership will cover the U.S. development of four Tanabe compounds: the muscle relaxant alaqualone, the oral cardiotonic agent denopamine, the synthetic penicillin antibiotic aspoxicillin, and the anticancer agent TA-077, the release notes. Alfaqualone is already being marketed in Japan by Tanabe, Marion said. The other three compounds are currently in development in Japan. "Though this venture with Marion, Tanabe will have an organization which is responsible for developing and registering Tanabe compounds with the U.S. FDA and the Canadian health authorities," the U.S. firm explained. "In the future, a joint venture corporation will be formed for manufacturing and marketing Tanabe compounds to be selected and agreed upon by both firms." Marion said that a name for the joint venture has not yet been determined. The U.S. firm also noted that final details of the arrangement are still being worked out and should be completed by this fall. The joint venture will be headquartered in Kansas City, Mo., where Marion is based. Marion is clearly an attractive partner for Tanabe based on the successful development and marketing of Cardizen. Although last to be approved among the currently marketed calcium channel blockers, Cardizem is now among the fastest growing new products on the U.S. market with projected sales of $60 mil. in FY 1984 (ended June 30) -- the cardiovascular agent's second year on the market. The release notes that "because of Marion's successful marketing of Cardizem in the U.S. and Canada, the joint venture will encompass potential analogues of diltiazem for use in the cardio/cerebrovascular fields as follow-up compounds." Tanabe is following the same approach to developing a U.S. presence as taken earlier by Takeda in its joint venture with Abbott, which now has four compounds awaiting FDA approval. The arrangement with Tanabe is Marion's third licensing agreement announced in the last five months, and represents the second time Marion has looked to Japan for R&D licensing in that period. In April, Marion announced a licensing agreement covering an isosorbide dinitrate transdermal patch with Japanese firms Electric Industrial and Toa Eiyo ("The Pink Sheet" April 23, p. 11), and a month ago Marion reported an agreement with Nova covering early stage R&D compounds ("The Pink Sheet" July 30, T&G-1).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts